^
    Back
    Association details:
    Biomarker:BIRC5 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    maveropepimut-S (MVP-S) (Survivin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    DPX-Survivac and Checkpoint Inhibitor in DLBCL

    Excerpt:
    ...To document the objective response rate using modified Cheson criteria to treatment with DPX-Survivac and low dose cyclophosphamide administered together with Pembrolizumab in participants with recurrent, survivin-expressing B cell lymphomas...
    Trial ID:
    SPiReL
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    DPX-Survivac and Checkpoint Inhibitor in DLBCL

    Excerpt:
    ...Subjects must have evidence of survivin expression in pre-treatment tumour sample (> 10% of tumour cells stained)....
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    2114 Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

    Published date:
    11/04/2020
    Excerpt:
    Analyses of peripheral blood T cell responses to survivin by ELISpot assay shows that 7/7 subjects who achieved an objective response have survivin-specific T cell response. One subject with PD also showed a survivin-specific T cell response, supporting the mechanism of action and the role of DPX-Survivac in anti-tumor activity.
    Secondary therapy:
    cyclophosphamide